Log in

Start Your Membership Now

On January 3, 2019, Otsuka America, Inc., and Click Therapeutics, Inc., announced that they signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of major depressive disorder (MDD). Otsuka has agreed to commit capital to fully fund development of Click's novel mobile application "CT-152" for MDD, and to commercialize this application world-wide upon achievement of regulatory approvals.

The CT-152 app will leverage evidence-based cognitive therapy principles and Click's patient engagement platform to treat patients either independently or in conjunction with prescribed pharmacotherapies. The intent is that the app will . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: